Zenas Biopharma Inc

Active Lockout Rally continuation with large green candles above rising EMAs drives forced participation despite extreme overbought conditions. Price sits in Stage 2 Advancing within a long-term uptrend, anchoring a medium-term bullish bias. A Lockout Rally override forces a bullish short-term timing decision, so we Buy Now to participate in the ongoing momentum above the 9/21 EMA with shallow pullbacks.

• ↑Stock climbed 12.64% over two weeks, reflecting robust momentum.
• ↑Analysts raised earnings forecasts; consensus price target at $44.29.
• ↓Earnings yield of –3.06 and low profitability hamper cash flow.